by nobilistx | Jun 8, 2021 | Uncategorized |
Nobilis Therapeutics is looking forward to connecting with investors, biotechnology and pharma companies at the upcoming BIO Digital Conference. The company will be updating conference participants on its recent advancements and will be discussing investment...
by nobilistx | Dec 8, 2020 | Uncategorized |
As one of the few selected companies Nobilis Therapeutics had the opportunity to present its technology in front of over 100 sophisticated investors. While we didn’t win, our presentation and the Q&A session were very well received and have started a number...
by nobilistx | Oct 22, 2020 | Uncategorized |
PORTLAND, Ore., October 22, 2020 – Nobilis Therapeutics announced today the issuance of a US Patent (US Patent No: 10,792,305 B2) for a patent titled “Therapeutic immune modulation using noble gas compositions.” One of it broadest claims includes “a method of treating...
by nobilistx | Jul 22, 2020 | Uncategorized |
Nobilis Therapeutics, a biopharmaceutical company today announced that the U.S. Food & Drug Administration (FDA) has allowed it to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with Panic Disorder. PORTLAND, ORE. (PRWEB) JULY...
by nobilistx | Jun 23, 2020 | Uncategorized |
Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase 2b clinical...
